Final Pivotal Trial Guidance Addresses Unblinded Device Studies

The FDA strongly recommends blinding in device pivotal trials, when possible, and notes that, even if the subject and/or the investigator cannot be blinded, devicemakers may be able to secure a blinded third-party evaluator to assess the study endpoints.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00